| Today’s Big NewsMar 28, 2025 |
|
Thursday, April 3, 2025 | 11am ET / 8am PT Join us for an insightful webinar on the latest advancements in cell and gene therapy, focusing on the innovative Cas9-CLIPT (Cleaved, Linearized with Protein Template) technology. Learn more about this groundbreaking technology designed to improve the efficiency of genome editing. Register now. 
|
|
| By Nick Paul Taylor Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to secure global rights to a preclinical prospect that paired well with its GLP-1 blockbuster semaglutide in mice. |
|
|
|
By Nick Paul Taylor BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xVEGF-A bispecific. The biotech linked BNT327 to a median overall survival of 16.8 months in a Chinese phase 2 trial, suggesting the drug candidate could set a new benchmark in a market served by AstraZeneca and Roche. |
By Darren Incorvaia,Zoey Becker CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the company’s executive team. Bruno had been with CRISPR for six years, serving in several management roles with increasing responsibility before landing the chief operating officer position last May. |
By James Waldron BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic antibodies while eking out its cash to cover a slew of clinical readouts over the next couple of years. |
By James Waldron Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases may be coming to an end before they really began. |
By James Waldron Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to also strip away its remaining pipeline. |
By Andrea Park,Conor Hale This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
By Kevin Dunleavy The FDA has rejected Milestone Pharmaceuticals’ application for approval of Cardamyst (etripamil), a nasal spray to quell symptomatic episodes from paroxysmal supraventricular tachycardia (PSVT), which is a type of abnormal heart rhythm. The regulator cited a two key manufacturing, chemistry and control issues that need to be addressed. |
By Angus Liu Novo Nordisk snagged an obesity asset from China's United Laboratories for up to $2 billion. Merck got an lp(a) inhibitor from Hengrui for cardiovascular disease. Hengrui and Elevar's PD-1 liver cancer combo was again tripped up by manufacturing at the FDA. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Tuesday, April 8, 2025 | 1pm ET / 10am PT Learn how AI-powered digital phenotyping and real-world data (RWD) help identify overlooked patient populations, bridge gaps between clinical guidelines and real-world treatment, and refine commercial strategies. Join experts to discover how AI-driven insights can optimize market positioning and ensure therapies reach the right patients. Register now! 
|
|
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
